84504-69-8

Product Details:

CasNo： 84504-69-8

Molecular Formula： C13H11Cl2N5O4

Purity： 99%

Synonyms: 2,4-diamino-6-(2,5-dichlorophenyl)-s-triazinemaleate; 3,5-triazine-2,4-diamine,6-(2,5-dichlorophenyl)-(z)-2-butenedioate; gaslon; mn-1695; 2,4-diamino-6-(2,5-dichlorophenyl)-1,3,5-triazine maleate; Irsogladin maleate; Gaslon N

Melting point: 181-182°C

Boiling point: 552.2ºC at 760 mmHg

Flash point: 287.8ºC

Form: Crystalline powder

Color: White to Almost white

Water Solubility: Insoluble in water

Solubility: DMF: 30.0(Max Conc. mg/mL); 80.61(Max Conc. mM).   DMSO: 30.0(Max Conc. mg/mL); 80.61(Max Conc. mM).  DMSO: PBS (pH 7.2) (1:3): 0.25(Max Conc. mg/mL); 0.67(Max Conc. mM)

Description:

Irsogladine is a gastroprotective agent. It increases transfer of Lucifer yellow CH between isolated rabbit gastric epithelial cells, indicating enhanced gap junction intercellular communication (GJIC). Irsogladine (3 mg/kg) inhibits gastric mucosal lesion formation and decreases in gastric mucosal blood flow induced by monochloramine in rats, effects that can be prevented by the nitric oxide synthase inhibitor L-NAME . It also inhibits superoxide anion production induced by fMLP and increases cAMP levels in isolated human neutrophils in a concentration-dependent manner, similar to the phosphodiesterase 4 (PDE4) inhibitor rolipram .

Uses:

Antiulcerative; Selective PDE4 inhibitor which also enhances gap junction intercellular communication.

Biological Activity:
Phosphodiesterase 4 (PDE4) inhibitor that displays gastroprotective properties.  Prevents gastric mucosal injury induced by monochloramine and ischemia-reperfusion.  Activates gap-junctional intercellular communication improving gastric mucosal barrier function.  Inhibits superoxide production in human neutrophils and inhibits in vitro and in vivo angiogenesis.